It was revealed that cancers from different systems shared similar contributions of CSCs in tumour post-treatment recurrences, including the evidence of upregulated CSC markers, such as CD133 and CD44 variants in recurrent tissues, which might act as predictive, prognostic, and therapeutic targets [183,184,185,186]. This evidence concerns the gene PROM1 and cancer.